Trial reportClinical and experimental immunology2010
Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.
Trial report in Clinical and experimental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Security of the Bronchial Allergen Provocation With Mite and Aspergillus and Predictors for a Positive Reaction.
Investigation of T-regulatory Cells After Subcutaneous Immunotherapy
Who cites it
21 citing papers in PubMed, 58 citations in OpenAlex.
- Heterogenous Induction of Blocking Antibodies against Ragweed Allergen Molecules by Allergen Extract-Based Immunotherapy Vaccines.Vaccines · 2024Article
- T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy.Heliyon · 2023Article
- A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1.The World Allergy Organization journal · 2023Article
- TLR Signals in Epithelial Cells in the Nasal Cavity and Paranasal Sinuses.Frontiers in allergy · 2021Review
- EAACI Allergen Immunotherapy User's Guide.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2020Review
- Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.Frontiers in immunology · 2020Review
- Food Allergies: Current and Future Treatments.Medicina (Kaunas, Lithuania) · 2019Review
- Immunostimulants in respiratory diseases: focus on Pidotimod.Multidisciplinary respiratory medicine · 2019Review
- The role of basophils as innate immune regulatory cells in allergy and immunotherapy.Human vaccines & immunotherapeutics · 2018Review
- Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.The Journal of allergy and clinical immunology · 2017Article
- Next generation immunotherapy for tree pollen allergies.Human vaccines & immunotherapeutics · 2017Review
- The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.Current allergy and asthma reports · 2017Review
- Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children With Grass Pollen Allergies.Allergy, asthma & immunology research · 2016Article
- The future of biologics: applications for food allergy.The Journal of allergy and clinical immunology · 2015Review
- Article
- SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.Expert review of vaccines · 2014Review
- New treatments for allergen immunotherapy.The World Allergy Organization journal · 2014Review
- Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.Infection and immunity · 2013Article
- Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells.Immunology · 2012Article
- Therapies for allergic inflammation: refining strategies to induce tolerance.Nature medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic diseases. A pollen allergoid formulated with the T helper type 1 (Th1)-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT. Little is known about mechanisms of tolerance induction in this setting. In a prospective study, 34 patients allergic to grass pollen (25 male, nine female, median age 10.2 years) received a total of 44 SIT courses (20 in the first, 24 in the second) with MPL-adjuvanted pollen allergoids. Immunogenicity was measured by levels of specific immunoglobulin G (IgG(grass)) and IgG4(grass) by antibody blocking properties on basophil activation, and by induction of CD4(+), CD25(+) and forkhead box P3 (FoxP3(+)) regulatory T cells (T(reg)). Specific IgG and IgG4 levels increased only slightly in the first year of SIT. In the second year these changes reached significance (P < 0.0001). In keeping with these findings, we were able to show an increase of T(reg) cells and a decreased release of leukotrienes after the second year of treatment. In the first year of treatment we found little evidence for immunological changes. A significant antibody induction was seen only after the second course of SIT. Short-course immunotherapy with pollen allergoids formulated with the Th1-inducing adjuvant MPL needs at least two courses to establish tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.